Condition
Hepatic Portal Vein Tumor Invasion
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Recruiting1
Terminated1
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05984511Not ApplicableRecruiting
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
NCT01690715Terminated
Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery
NCT02149771Phase 3Withdrawn
Combination Treatment for Advanced Liver Cancer
Showing all 3 trials